National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®)
Patient Version   Health Professional Version   En español   Last Modified: 02/20/2009



Purpose of This PDQ Summary






General Information






Cellular Classification and Prognostic Variables






Treatment Option Overview






Untreated Childhood Acute Lymphoblastic Leukemia






Childhood Acute Lymphoblastic Leukemia in Remission






Postinduction Treatment for Childhood Acute Lymphoblastic Leukemia Subgroups






Recurrent Childhood Acute Lymphoblastic Leukemia






Get More Information From NCI






Changes to this Summary (02/20/2009)






More Information



Page Options
Print This Page
Print Entire Document
View Entire Document
E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
Quit Smoking Today
NCI Highlights
The Nation's Investment in Cancer Research FY 2010

Report to Nation Finds Declines in Cancer Incidence, Death Rates

High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Changes to this Summary (02/20/2009)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

General Information

Cited Möricke et al. as reference 27 and level of evidence 2Di.

Cellular Classification and Prognostic Variables

Cited Borowitz et al. as reference 134 and level of evidence 3iiDi.

Added text to state that for patients with high hyperdiploidy and unfavorable trisomies, higher levels of minimal residual disease at the end of induction therapy appear to be associated with higher risk of subsequent relapse.

Untreated Childhood Acute Lymphoblastic Leukemia

Cited Möricke et al. as reference 33 and level of evidence 2Di.

Childhood Acute Lymphoblastic Leukemia in Remission

Added text to state that some regimens extend maintenance therapy for boys based on the high risk of relapse (added Möricke et al. as reference 22 and level of evidence 2Di).

Back to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov